Redefining Treatment Approaches in Advanced HCC
EP. 1: Management Challenges of Advanced HCC
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine Richard S. Finn, MD, leads a panel of experts in a discussion around key updates from the 2021 ASCO GI virtual meeting, and a review of the rapidly evolving landscape for unresectable advanced hepatocellular carcinoma.
EP. 2: Practical Considerations of TACE in HCC
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine A panel of experts discuss practical considerations for TACE in patients with unresectable BCLC stage B HCC, as well as define TACE-refractoriness and what to do if a patient fails treatment.
EP. 3: Recent Findings in Systemic Therapy for Patients With BCLC Stage B HCC
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine Amit G. Singal, MD, MS, leads a review of recent data around the outcomes of systemic therapy for patients with BCLC stage B HCC.
EP. 4: TACE and Systemic Therapy in HCC
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine An in-depth discussion about the role of TACE in combination with systemic therapies for the treatment of HCC.
EP. 5: Combination Therapy for HCC Treatment
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine Experts discuss recent data surrounding emerging combinations of TACE plus systemic therapies for patients with BCLC stage B or C HCC.
EP. 6: A New Standard of Care for Liver Cancer Treatment
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine A discussion about the recent data from trials that looked at atezolizumab-bevacizumab for the treatment of advanced HCC, and its role as the new standard of care.
EP. 7: Personal Experience Using Atezolizumab-Bevacizumab in HCC Treatment
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine Laura M. Kulik, MD, leads a discussion about personal experiences using atezolizumab-bevacizumab and whether clinical trial data reflect real-world experience.
EP. 8: Considerations for Later Lines of Therapy in HCC Treatment
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine Experts in the field of HCC consider second and third lines of therapy after a patient’s disease state progresses after frontline atezolizumab-bevacizumab.
EP. 9: Treatment Strategies for Childs-Pugh B Disease
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine Experts expand on treatment strategies and sequencing approaches used for Child-Pugh B liver disease.
EP. 10: Role of TKIs in HCC Treatment
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine An examination of the use of second-line therapies after atezolizumab-bevacizumab, and the role of TKIs for the treatment of advanced HCC.
EP. 11: Ongoing Data for First-line Combinations in HCC
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine A summary of updates that explore ongoing data from various frontline combinations in unresectable HCC.
EP. 12: HCC Treatment: Emerging Data in IO Combinations
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine Experts discuss emerging data in immunotherapy combination approaches for the treatment of advanced HCC.
EP. 13: Role of Single Agent IO in Hepatocellular Carcinoma Frontline Therapies
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine,Amit Singal, MD, UT Southwestern Medical Center A summary of ongoing clinical data that explore the use of frontline single agent immunotherapy in advanced HCC.
EP. 14: Challenges of Sequencing and Biomarkers in Hepatocellular Carcinoma
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine,Amit Singal, MD, UT Southwestern Medical Center Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.
EP. 15: Final Thoughts on the Future of Liver Cancer
ByRichard S. Finn, MD, UCLA Health,Daniel H. Ahn, DO, Mayo Clinic,Laura M. Kulik, MD, Northwestern,Daneng Li, MD, City of Hope,Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine,Amit Singal, MD, MS, UT Southwestern Medical Center A panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.
